LifeArc Ventures

LifeArc Ventures LifeArc Ventures is part of LifeArc, a medical research charity with a remarkable funding model. it's self-financing through royalties from Keytruda (sold to CPPIB for $1.297B in 2019), giving it a substantial permanent capital base. The strategy is to invest £1.3B by 2030, and the portfolio has expanded from 14 companies in 2022 to 20 by end- 2025, investing across therapeutics, HealthTech, and medical devices at seed and Series A stages. Recent activity demonstrates both the